Pei-pei Fang1,
Jie Li1,
Shan-shan Huang1,
Chen-wei Pan1,
Guang-yao Zhou1,
Lingxiang Jin1,
Lu Zhuge1,
Le Qin2 
For correspondence:- Le Qin Email: Qinle9105@163.com
Accepted: 26 March 2018 Published: 30 April 2018
Citation: Fang P, Li J, Huang S, Pan C, Zhou G, Jin L, et al. Lentinan relieves hepatitis B surface antigen induced functional impairment of monocytes/macrophages. Trop J Pharm Res 2018; 17(4):583-588 doi: 10.4314/tjpr.v17i4.3
© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the efficacy of lentinan in relieving hepatitis B surface antigen (HBsAg)-induced functional impairment of monocytes/macrophages.
Methods: Monocytic cell line THP-1 was incubated with lentinan and HBsAg for 24 h and then stimulated with LPS (Lipopolysaccharide). The ex
Results: THP-1 cells treated with lentinan and HBsAg showed higher IL-1β, IL-12, and TNF-α levels than cells treated with HBsAg alone. The underlying mechanisms were associated with NF-kB and MAPK signal pathways. Decreased ex
Conclusion: Lentinan shows both pro- and anti-inflammatory functions and may be a promising candidate for hepatitis B virus (HBV) treatment.
Archives
News Updates
Fulltext in PDF